<DOC>
	<DOCNO>NCT00118352</DOCNO>
	<brief_summary>This phase II trial study side effect best dose alemtuzumab give together fludarabine phosphate total-body irradiation follow cyclosporine mycophenolate mofetil treat patient undergo donor stem cell transplant hematologic cancer . Giving low dos chemotherapy , fludarabine phosphate , monoclonal antibody , alemtuzumab , radiation therapy donor stem cell transplant help stop growth cancer cell . Giving chemotherapy radiation therapy transplant also stop patient 's immune system reject donor 's bone marrow stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Alemtuzumab , Fludarabine Phosphate , Total-Body Irradiation Followed Cyclosporine Mycophenolate Mofetil Treating Patients Who Are Undergoing Donor Stem Cell Transplant Hematologic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine dose Campath ( alemtuzumab ) allow relate unrelated human leukocyte antigen ( HLA ) class-II mismatch hematopoietic cell transplantation ( HCT ) incidence grade III-IV acute graft-versus-host disease ( GVHD ) less 40 % . SECONDARY OBJECTIVES : I . Incidence graft rejection . II . Number day steroid &gt; = 1mg/kg require day 100 patient . III . Incidence non-relapse mortality . IV . Risk/incidence infection . V. Immune reconstitution . VI . Risk disease progression relapse . OUTLINE : This dose-escalation study alemtuzumab . NONMYELOABLATIVE CONDITIONING REGIMEN : Patients receive alemtuzumab intravenously ( IV ) 6 hour daily day -6 , -5 , -4 OR day -5 -4 fludarabine phosphate IV 30 minute day -4 , -3 , -2 . Patients also undergo low-dose total-body irradiation ( TBI ) day 0 . ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION ( PBSCT ) : After completion TBI , patient undergo allogeneic PBSCT day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine orally ( PO ) IV every 12 hour day -3 180 followed taper day 365 absence GVHD . Beginning 4-6 hour completion allogeneic PBSCT , patient receive mycophenolate mofetil PO every 8 hour day 0 100 follow taper day 156 absence GVHD . After completion study treatment , patient follow periodically 12 month , 18 month , annually 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Leukemia , Mast-Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>The patient must eligible conventional transplant must disease expect stable least 100 day without chemotherapy Patients hematologic malignancy treatable HCT include : Aggressive nonHodgkin lymphoma ( NHLs ) histologies diffuse large Bcell NHL : eligible autologous HCT , eligible conventional myeloablative HCT , fail autologous HCT ; Low grade NHL : &lt; 6 month duration complete response ( CR ) course conventional therapy ; Mantle cell NHL : may treat first CR ; Chronic lymphocytic leukemia ( CLL ) : must fail 2 line conventional therapy must refractory fludarabine ; include patient fail complete partial response therapy regimen contain fludarabine ( another nucleoside analog ] experience disease relapse within 12 month complete therapy regimen contain fludarabine [ another nucleoside analog ) ; Hodgkin 's disease ( HD ) : must receive failed frontline therapy fail eligible autologous transplant ; Multiple myeloma ( MM ) : must receive prior chemotherapy fail autografting ; follow plan autologous transplant [ tandem ] allow ; Acute myeloid leukemia ( AML ) : must &lt; 5 % marrow blast time transplant ; Acute lymphocytic leukemia ( ALL ) : must &lt; 5 % marrow blast time transplant ; Chronic myelogenous leukemia ( CML ) : patient accept beyond first clinical progression ( CP1 ) receive previous myelosuppressive chemotherapy HCT , &lt; 5 % marrow blast time transplant ; Myelodysplastic syndrome/myeloproliferative disease ( MDS/MPD ) : must fail previous myelosuppressive chemotherapy HCT , &lt; 5 % marrow blast time transplant ; Waldenstrom 's macroglobulinemia : must fail 2 course therapy Patient refuse treat conventional transplant protocol ; inclusion criterion , transplant must approve participate institution 's patient review committee , Patient Care Conference ( PCC ) Fred Hutchinson Cancer Research Center ( FHCRC ) , FHCRC principal investigator Patient relate unrelated donor : There likelihood disease progression HLA type result preliminary search donor pool suggest 10/10 HLAA , B , C , DRB1 DQB1 match unrelated donor find ; Patient donor must match least one DRB1 allele one DQB1 allele ; Best available match HLA class I HLAA , B , C allele match donor allow one two DRB1 and/or DQB1 antigen/allele mismatch ; There indication autologous transplantation treatment option DONOR : For HLA match inclusion criterion , see patient inclusion criterion DONOR : Only peripheral blood stem cell ( PBSC ) permit HSC source protocol Positive crossmatch donor recipients Patient 's life expectancy severely limited disease malignancy Patient central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy Presence circulate leukemic blast ( peripheral blood ) detect standard pathology patient AML , ALL CML Patient fertile man woman unwilling use contraceptives 12 month post treatment Patient female pregnant breastfeeding Patient human immunodeficiency virus ( HIV ) positive Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence Patient fungal infection radiological progression receipt amphotericin B active triazole great 1 month Patient follow organ dysfunction : Symptomatic coronary artery disease ejection fraction &lt; 35 % cardiac failure require therapy ; ejection fraction require age &gt; 50 year patient history anthracyclines history cardiac disease ; Diffusion capacity lung carbon monoxide ( DLCO ) &lt; 35 % total lung capacity ( TLC ) &lt; 35 % , forced expiratory volume lung one second ( FEV1 ) &lt; 35 % and/or receive supplementary continuous oxygen ; FHCRC study principal investigator ( PI ) must approve enrollment patient pulmonary nodule ; Liver function abnormality : patient clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function , bridge fibrosis , degree portal hypertension ; patient exclude he/she find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3mg/dL , symptomatic biliary disease Patient poorly control hypertension multiple antihypertensives Karnofsky performance score &lt; 70 adult patient Lansky playperformance score &lt; 70 pediatric patient Patient receive cytotoxic agent `` cytoreduction '' within three week ( interval cycle standard chemotherapy would administer nontransplant setting ) prior initiate nonmyeloablative transplant conditioning ; ( exception hydroxyurea imatinib mesylate ) DONOR : Marrow donor DONOR : Positive crossmatch donor recipient DONOR : Donor HIVpositive and/or medical condition would result increase risk filgrastim ( GCSF ) mobilization harvest PBSC DONOR : Donor age &lt; 12 year</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>